|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
57,730,000 |
Market
Cap: |
2.91(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$20.06 - $59.99 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Merus is a clinical-stage oncology company developing antibody therapeutics. Using its Biclonics® platform, Co. has produced and is developing the following candidates: MCLA-128 (zenocutuzumab) for the treatment of solid tumors that harbor Neuregulin 1 gene fusions; MCLA-117 for the treatment of acute myeloid leukemia; MCLA-158 for the treatment of solid tumors; and MCLA-145, developed in collaboration with Incyte Corporation, for the potential treatment of solid tumors and a hematological malignancy, B-cell lymphoma. Co. is also developing a late-stage pre-clinical candidate, MCLA-129 in collaboration with Betta Pharmaceuticals Co. Ltd., for the potential treatment of solid tumors.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
25,576 |
Total Buy Value |
$0 |
$0 |
$0 |
$460,861 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
4 |
Total Shares Sold |
0 |
22,751 |
23,326 |
24,809 |
Total Sell Value |
$0 |
$568,828 |
$582,962 |
$610,480 |
Total People Sold |
0 |
2 |
2 |
2 |
Total Sell Transactions |
0 |
3 |
4 |
8 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
De Kruif John |
SVP & Chief Technology Officer |
|
2021-08-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,572 |
18,069 |
|
- |
|
Lundberg Sven Ante |
President, CEO & PFO |
|
2021-08-02 |
4 |
OE |
$12.54 |
$200,474 |
D/D |
15,000 |
15,000 |
|
- |
|
Bakker Lex |
SVP, Chief Development Officer |
|
2021-07-02 |
4 |
OE |
$1.93 |
$13,510 |
D/D |
7,000 |
15,668 |
|
- |
|
Lampert Mark N |
10% Owner |
|
2021-07-02 |
4 |
S |
$20.75 |
$45,359,957 |
D/D |
(2,186,022) |
311,210 |
|
-30% |
|
Bakker Lex |
SVP, Chief Development Officer |
|
2021-07-01 |
4 |
AS |
$21.00 |
$81,242 |
D/D |
(3,860) |
8,668 |
|
32% |
|
Lampert Mark N |
10% Owner |
|
2021-03-30 |
4 |
B |
$19.75 |
$5,925,000 |
D/D |
300,000 |
462,015 |
2.45 |
-3% |
|
Lundberg Sven Ante |
President, CEO & PFO |
|
2021-03-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
74,000 |
0 |
|
- |
|
Lampert Mark N |
10% Owner |
|
2021-03-22 |
4 |
B |
$22.75 |
$1,808,625 |
D/D |
79,500 |
435,121 |
2.45 |
-26% |
|
Lampert Mark N |
10% Owner |
|
2021-03-16 |
4 |
B |
$23.00 |
$5,749,900 |
D/D |
250,000 |
427,377 |
2.45 |
-28% |
|
Lundberg Sven Ante |
President, CEO & PFO |
|
2021-03-01 |
4 |
OE |
$12.54 |
$989,867 |
D/D |
74,000 |
74,000 |
|
- |
|
Incyte Corp |
10% Owner |
|
2021-01-25 |
4 |
A |
$24.75 |
$8,662,500 |
D/D |
350,000 |
3,550,000 |
|
- |
|
Lampert Mark N |
10% Owner |
|
2021-01-21 |
4 |
B |
$24.75 |
$20,905,830 |
D/D |
844,680 |
426,206 |
2.45 |
-26% |
|
Liu Hui |
EVP, CBO & Head of Merus US |
|
2021-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
578 |
57,931 |
|
- |
|
De Kruif John |
SVP & Chief Technology Officer |
|
2021-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
58 |
12,497 |
|
- |
|
Bakker Lex |
SVP, Chief Development Officer |
|
2021-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
91 |
5,162 |
|
- |
|
Lampert Mark N |
10% Owner |
|
2020-12-18 |
4 |
B |
$16.05 |
$2,568,000 |
D/D |
160,000 |
2,245,067 |
2.45 |
31% |
|
Liu Hui |
EVP, CBO & Head of Merus US |
|
2020-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
582 |
57,353 |
|
- |
|
Bakker Lex |
SVP, Chief Development Officer |
|
2020-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
108 |
5,071 |
|
- |
|
De Kruif John |
SVP & Chief Technology Officer |
|
2020-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
79 |
12,439 |
|
- |
|
Liu Hui |
EVP, CBO & Head of Merus US |
|
2020-11-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
582 |
56,771 |
|
- |
|
Bakker Lex |
SVP, Chief Development Officer |
|
2020-11-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
108 |
4,963 |
|
- |
|
De Kruif John |
SVP & Chief Technology Officer |
|
2020-11-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
79 |
12,360 |
|
- |
|
Liu Hui |
EVP, CBO & Head of Merus US |
|
2020-10-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
582 |
56,189 |
|
- |
|
Bakker Lex |
SVP, Chief Development Officer |
|
2020-10-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
108 |
4,855 |
|
- |
|
De Kruif John |
SVP & Chief Technology Officer |
|
2020-10-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
79 |
12,281 |
|
- |
|
108 Records found
|
|
Page 2 of 5 |
|
|